Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer
Referencias
Additional references
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine 2014;371(5):424‐33.
Berruti A, Tucci M, Mosca A, Tarabuzzi R, Gorzegno G, Terrone C, et al. Predictive factors for skeletal complications in hormone‐refractory prostate cancer patients with metastatic bone disease. British Journal of Cancer2005; Vol. 93, issue 6:633‐6.
Botrel TEA, Clark O, Lima Pompeo AC, Horta Bretas FF, Sadi MV, Ferreira U, et al. Efficacy and safety of combined androgen deprivation therapy (ADT) and docetaxel compared with ADT alone for metastatic hormone‐naive prostate cancer: a systematic review and meta‐analysis. PloS One 2016;11:6.
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU‐ESTRO‐SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration‐resistant prostate cancer. European Urology 2017;71(4):630‐42.
Veritas Health Innovation. Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 25 July 2017.
Darshan MS, Loftus MS, Thadani‐Mulero M, Levy BP, Escuin D, Zhou XK, et al. Taxane‐Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer. Cancer Research 2011;71(18):6019‐29.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration‐resistant prostate cancer progressing after docetaxel treatment: a randomised open‐label trial. Lancet2010; Vol. 376, issue 9747:1147‐54.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu Luis, et al. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine2011; Vol. 364, issue 21:1995‐2005.
Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Engels FK, Sparreboom A, Mathot RAA, Verweij J. Potential for improvement of docetaxel‐based chemotherapy: a pharmacological review. British Journal of Cancer2005; Vol. 93, issue 2:173‐7.
Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Research 2009;69(21):8386‐94.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advance prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology 2015;26(8):1589‐604.
McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 25 July 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Schünemann HJ, et al. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.) 2008;336(7651):995‐8. [DOI: 10.1136/bmj.39490.551019.BE]
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. [DOI: 10.1016/j.jclinepi.2010.04.026]
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10‐Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine2016; Vol. 375, issue 15:1415‐24.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. [DOI: 10.1002/sim.1186]
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557‐60. [DOI: 10.1136/bmj.327.7414.557]
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. the effects of castration on advanced carcinoma of the prostate gland. Archives of Surgery1941; Vol. 43, issue 2:209‐23.
Inoue T, Segawa T, Kamba T, Yoshimura K, Nakamura E, Nishiyama H, et al. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology2009; Vol. 73, issue 5:1104‐9.
James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the "docetaxel era": data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). European Urology 2015;67(6):1028‐38.
Janknegt RA, Boon TA, van de Beek C, Grob P. Combined hormone/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology 1997;49(3):411‐20.
Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Research1996; Vol. 56, issue 4:816‐25.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel‐T immunotherapy for castration‐resistant prostate cancer. New England Journal of Medicine2010; Vol. 363, issue 5:411‐22.
Kirby M, Hirst C, Crawford ED. Characterising the castration‐resistant prostate cancer population: a systematic review. International Journal of Clinical Practice2011; Vol. 65, issue 11:1180‐92.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100]
Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparrebom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clinical Pharmacology and Therapeutics2003; Vol. 74, issue 4:364‐71.
Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. Journal of Clinical Oncology 2008;26(36):5936‐42.
Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. National Comprehensive Cancer Network2017.
Murphy GP, Beckley S, Brady MF, Ming CT, Dekernion JB, Dhabuwala C, et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983;51(7):1264‐72.
Parker G, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Annals of Oncology 2015;26(Suppl 5):v69‐v77.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.
Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine2004; Vol. 351, issue 15:1513‐20.
Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. European Urology 1997;32 Suppl 3:81‐5.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ryan CJ, Smith MR, Fizazi F, Mulders PFA, Sternberg CN, Miller K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy‐naive men with metastatic castration‐resistant prostate cancer (COU‐AA‐302): final overall survival analysis of a randomised, double‐blind, placebo‐controlled phase 3 study. Lancet Oncology 2015;16(2):152‐60.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine2012; Vol. 367, issue 13:1187‐97.
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a Cancer Journal for Clinicians 2016;66(1):7‐30.
Taguchi T, Furue H, Niitani H, Ishitani K, Kanamaru R, Hasegawa K, et al. Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug. Gan To Kagaku Ryoho1994; Vol. 21, issue 12:1997‐2005.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine2004; Vol. 351, issue 15:1502‐12.
Templeton AJ, Vera‐Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz‐Amit R, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Annals of Oncology 2013;24(12):2972‐7.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16.
Tilki D, Schaeffer EM, Evans CP. Understanding mechanisms of resistance in metastatic castration‐resistant prostate cancer: the role of the androgen receptor. European Urology Focus2016; Vol. 2, issue 5:499‐505.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a Cancer Journal for Clinicians 2015;65:87‐108.
Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone‐sensitive metastatic prostate cancer: a systematic review and meta‐analysis. European Urology2016; Vol. 69, issue 4:563‐73.
Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone‐sensitive prostate cancer: a systematic review and meta‐analyses of aggregate data. Lancet Oncology 2016;17(2):243‐56.
Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. Journal of Clinical Oncology2010; Vol. 28, issue 9:1508‐13.
Zhu ML, Horbinski C, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin‐targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Research2010; Vol. 70, issue 20:7992‐8002.
